Research Article
Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma
Table 1
Patients’ characteristics.
| | Characteristic | All patients ()
(%) | Exposed to asbestos ()
(%) |
| | Gender | | | | Male | 66 (84.6) | 54 (85.7) | | Female | 12 (15.4) | 9 (14.3) | | Age | | | | Years, median (25–75%) | 64.0 (57.8–70.3) | 65.0 (58.0–70.0) | | Asbestos exposure | | | | Exposed | 63 (80.8) | 63 (100.0) | | Unexposed | 15 (19.2) | | | Smoking | | | | Nonsmokers | 36 (46.2) | 30 (47.6) | | Smokers | 42 (53.8) | 33 (52.4) | | Stage | | | | I | 6 (7.7) | 6 (9.5) | | II | 21 (26.9) | 17 (27.0) | | III | 26 (33.3) | 19 (30.2) | | IV | 18 (23.1) | 17 (27.0) | | Peritoneal | 7 (9.0) | 4 (6.3) | | Histological type | | | | Epitheloid | 60 (76.9) | 48 (76.2) | | Biphasic | 11 (14.1) | 10 (15.9) | | Sarcomatoid | 4 (5.1) | 3 (4.8) | | Not characterized | 3 (3.8) | 2 (3.2) | | Eastern Cooperative Oncology Group performance status | | | | 0 | 33 (42.3) | 28 (44.4) | | 1 | 26 (33.3) | 21 (33.3) | | 2 | 19 (24.4) | 14 (22.2) | | CRP | | | | mg/L, median (25–75%) | 21 (6–62) | 22 (6–58) | | First-line chemotherapy | | | | Gemcitabine and cisplatin | 53 (67.9) | 43 (68.3) | | Pemetrexed and cisplatin | 25 (32.1) | 20 (31.7) | | Response rate | | | | CR or PR | 29 (37.7) | 23 (37.1) | | SD or progress | 48 (62.3) | 39 (62.9) | | Overall survival | | | | Months, median (25–75%) | 20.0 (11.6–47.8) | 18.0 (11.6–28.7) | | Progression-free survival | | | | Months, median (25–75%) | 7.9 (5.6–13.9) | 7.8 (5.6–13.1) |
|
|
Data missing for 1 patient; CR: complete response; : number of patients; PR: partial response; SD: stable disease.
|
